ClinicalTrials.Veeva

Menu
N

Northeast Research Institute | Fleming Island, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Semaglutide
Tirzepatide
Sugar
LY3298176
LY3841136
Retatrutide
LY3305677
Insulin aspart
NN0519-0130
NNC0519-0130

Parent organization

This site is a part of Northeast Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 26 total trials

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3305677
Drug: LY3549492

This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 differen...

Active, not recruiting
Obesity
Drug: Placebo
Drug: Tirzepatide

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney funct...

Enrolling
Chronic Kidney Disease
Drug: Placebo
Drug: Semaglutide

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine...

Active, not recruiting
Obesity
Drug: Cagrilintide
Drug: Tirzepatide

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 s...

Active, not recruiting
Obesity
Drug: Placebo cagrilintide
Drug: Cagrilintide
Locations recently updated

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participan...

Active, not recruiting
Overweight
Type 2 Diabetes Mellitus
Drug: Placebo semaglutide
Drug: Placebo cagrilintide

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (m...

Active, not recruiting
Type 2 Diabetes
Drug: IcoSema
Drug: Insulin glargine

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesit...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Active, not recruiting
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3305677

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Active, not recruiting
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3841136

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3549492

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ina...

Enrolling
Diabetes Type 2
Drug: Placebo
Drug: Retatrutide

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ren...

Enrolling
Type 2 Diabetes
Drug: Retatrutide
Drug: Placebo

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Novo Nordisk logo
Lilly logo
F
Mylan logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems